💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ramelteon

CHEMBL1218 Phase 4 Aprovado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
259.3 g/mol
LogP
2.7
Phase
4

A melatonin receptor agonist used to treat insomnia characterized by difficulty falling asleep, working by mimicking the natural sleep-regulating hormone melatonin. Unlike many sleep medications, it does not carry a risk of dependence or abuse.

Peso Molecular

259,3400 g/mol

LogP

2,70

TPSA

38,30 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Asthma Chronic Obstructive Pulmonary Disease Parkinson's Disease Migraine Schizophrenia Bipolar Disorder Insomnia Gastroesophageal Reflux Disease Hypertension Major Depressive Disorder

Mecanismo de Ação

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Estrutura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3

                

                

                
                

                    
InChI

                    
InChI=1S/C16H21NO2/c1-2-15(18)17-9-7-12-4-3-11-5-6-14-13(16(11)12)8-10-19-14/h5-6,12H,2-4,7-10H2,1H3,(H,17,18)/t12-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C16H21NO2

                    

                    
                    

                        
HBD / HBA

                        
1 / 2

                    

                    
                    

                        
Ligações Rotacionáveis

                        
4

                    

                    
                    
                    

                        
Átomos Pesados

                        
19

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Perguntas frequentes

                

                    
                    

                        
                        

                            
A melatonin receptor agonist used to treat insomnia characterized by difficulty falling asleep, working by mimicking the natural sleep-regulating hormone melatonin. Unlike many sleep medications, it does not carry a risk of dependence or abuse.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Ramelteon is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1218.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 208902.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Aviso Médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.